Seagen veteran-led ProfoundBio gets $55M to bring cancer drugs to the clinic

ProfoundBio is developing a type of targeted cancer therapy called antibody drug conjugates. As the biotech looks ahead to clinical trials, it has raised more than $55 million in Series A funding.